Dyne Therapeutics Introduces Breakthrough DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Dyne Therapeutics has introduced DYNE-101 as the first and only investigational therapy to receive FDA Breakthrough Therapy designation for the treatment of myotonic dystrophy type 1 (DM1).
DYNE-101 is designed to deliver an antisense oligonucleotide (ASO) to muscle and central nervous system tissue, targeting the toxic RNA that causes the underlying dysfunction in DM1. The therapy aims to reduce RNA toxicity and improve muscle function, mobility, and overall quality of life for affected individuals.
There are currently no approved therapies that can alter the course of DM1, which impacts tens of thousands of people in the U.S. and Europe.
The FDA’s Breakthrough Therapy designation highlights the potential of DYNE-101 to address this high unmet medical need. The therapy has previously received Orphan Drug and Fast Track designations, further emphasising its promise in treating DM1.
DM1 is characterised by progressive muscle weakness, myotonia, cardiac issues, and cognitive impairments. In clinical trials, DYNE-101 has demonstrated sustained improvements across multiple functional endpoints, including mobility and muscle strength. Notably, long-term data from the ACHIEVE trial showed continued benefit at 12 months, with no serious treatment-related adverse events reported.
DYNE-101 is the first and only investigational therapy to receive U.S. FDA Breakthrough Therapy designation for the treatment of myotonic dystrophy type 1.
